A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3667
Status:
Completed
Trial end date:
2020-07-06
Target enrollment:
Participant gender:
Summary
This study is a first-in-human, Phase I, randomized, double-blind, placebo-controlled,
single-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics
(PK) and pharmacodynamics of GLPG3667 after oral single ascending doses (SAD) of GLPG3667
(part 1) and after oral multiple ascending doses (MAD) for 13 days of GLPG3667 (part 2) in
healthy male subjects. In addition, the effect of food (FE) on safety, tolerability, and PK
of GLPG3667 oral suspension will be evaluated (part 3 - will not be completed), and the
relative bioavailability (rBA) of the capsule versus the oral suspension with the effect of
food on the bioavailability of the capsule (part 4), both part 3 and 4 using an open-label,
randomized, crossover design.